Cargando…

Biologics and Biosimilars in Psoriasis

Psoriasis is a chronic, debilitating, relapsing, inflammatory dermatosis, which affects approximately 2-3% of the population. The burgeoning research on pathogenesis of psoriasis has opened up new directions in management of this common condition. The introduction of biologics has given additional e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Sk Shahriar, De, Abhishek, Das, Sudip, Manchanda, Yashpal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389141/
https://www.ncbi.nlm.nih.gov/pubmed/37529455
http://dx.doi.org/10.4103/ijd.ijd_421_23
_version_ 1785082234534887424
author Ahmed, Sk Shahriar
De, Abhishek
Das, Sudip
Manchanda, Yashpal
author_facet Ahmed, Sk Shahriar
De, Abhishek
Das, Sudip
Manchanda, Yashpal
author_sort Ahmed, Sk Shahriar
collection PubMed
description Psoriasis is a chronic, debilitating, relapsing, inflammatory dermatosis, which affects approximately 2-3% of the population. The burgeoning research on pathogenesis of psoriasis has opened up new directions in management of this common condition. The introduction of biologics has given additional elements to the arsenal of psoriatic disease treatments. TNF-α inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, CD-6 inhibitor proved highly efficient and have a good safety profile in numerous clinical trials. Biosimilar drugs are structurally almost similar to their reference biologic and are also made from living organism. Long-term follow-up and post-marketing surveillance are required to understand, long-term efficacy, adverse events of these powerful potent molecules.
format Online
Article
Text
id pubmed-10389141
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103891412023-08-01 Biologics and Biosimilars in Psoriasis Ahmed, Sk Shahriar De, Abhishek Das, Sudip Manchanda, Yashpal Indian J Dermatol Symposium Article Psoriasis is a chronic, debilitating, relapsing, inflammatory dermatosis, which affects approximately 2-3% of the population. The burgeoning research on pathogenesis of psoriasis has opened up new directions in management of this common condition. The introduction of biologics has given additional elements to the arsenal of psoriatic disease treatments. TNF-α inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, CD-6 inhibitor proved highly efficient and have a good safety profile in numerous clinical trials. Biosimilar drugs are structurally almost similar to their reference biologic and are also made from living organism. Long-term follow-up and post-marketing surveillance are required to understand, long-term efficacy, adverse events of these powerful potent molecules. Wolters Kluwer - Medknow 2023 /pmc/articles/PMC10389141/ /pubmed/37529455 http://dx.doi.org/10.4103/ijd.ijd_421_23 Text en Copyright: © 2023 Indian Journal of Dermatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Symposium Article
Ahmed, Sk Shahriar
De, Abhishek
Das, Sudip
Manchanda, Yashpal
Biologics and Biosimilars in Psoriasis
title Biologics and Biosimilars in Psoriasis
title_full Biologics and Biosimilars in Psoriasis
title_fullStr Biologics and Biosimilars in Psoriasis
title_full_unstemmed Biologics and Biosimilars in Psoriasis
title_short Biologics and Biosimilars in Psoriasis
title_sort biologics and biosimilars in psoriasis
topic Symposium Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389141/
https://www.ncbi.nlm.nih.gov/pubmed/37529455
http://dx.doi.org/10.4103/ijd.ijd_421_23
work_keys_str_mv AT ahmedskshahriar biologicsandbiosimilarsinpsoriasis
AT deabhishek biologicsandbiosimilarsinpsoriasis
AT dassudip biologicsandbiosimilarsinpsoriasis
AT manchandayashpal biologicsandbiosimilarsinpsoriasis